HAON Life Science Secures $10.7M Grant to Fast-Track Off-The-Shelf Cell Therapies for Serious Diseases

HAON Life Science is excited to announce a major milestone in its mission to redefine treatment for neurological, rare, and other serious diseases by successfully raising $10,700,000 in its latest funding round. This substantial investment marks a significant step forward in advancing HAON’s pioneering pipeline of off-the-shelf cell therapies, utilizing the cutting-edge Can-Vas platform. The raised funds will accelerate key areas of translational research, clinical development, and cell manufacturing, ensuring that these innovative therapies can be delivered to patients faster and at a larger scale than ever before. As a biotech company on the forefront of investigational allogeneic candidates, HAON Life Science remains deeply committed to transforming patient outcomes by addressing critical gaps in treatment options. This fresh injection of capital will empower our world-class team to scale our investigations into investigational cell therapies, drive strategic partnerships, and expand our production capabilities, paving the way toward the introduction of transformative treatments in the clinical arena. By advancing our research and development efforts, HAON Life Science aims to bring life-changing therapies to those who need them most, ultimately helping to extend and improve the quality of life for patients facing life-threatening conditions. With our innovative approach and dedicated team, we are poised to not only accelerate our cell therapy pipeline but also to create new opportunities for hope and healing in communities worldwide. For more information on our mission and progress, please reach out to us on LinkedIn or via email at info@haonco.com, and join us as we continue to drive the future of cell therapy innovation.